In the last trading session, 3.04 million Citius Pharmaceuticals Inc. (NASDAQ:CTXR) shares changed hands as the company’s beta touched 1.54. With the company’s per share price at $2.08 changed hands at -$0.02 or -0.95% during last session, the market valuation stood at $306.59M. CTXR’s last price was a discount, traded about -119.23% off its 52-week high of $4.56. The share price had its 52-week low at $0.86, which suggests the last value was 58.65% up since then. When we look at Citius Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 3.65 million shares, with the 3-month average coming to 8.25 million.
Analysts gave the Citius Pharmaceuticals Inc. (CTXR) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CTXR as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Citius Pharmaceuticals Inc.’s EPS for the current quarter is expected to be -$0.06.
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) trade information
Instantly CTXR was in red as seen at the end of in last trading. With action -2.80%, the performance over the past five days has been red. The drop to weekly highs of 2.28 on Friday, 09/10/21 subtracted -0.95% to the stock’s daily price. The company’s shares are showing year-to-date upside of 103.92%, with the 5-day performance at -2.80% in the red. However, in the 30-day time frame, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is 13.04% up. Looking at the short shares, we see there were 13.7 million shares sold at short interest cover period of 4.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is $10.00, meaning bulls need an upside of 79.2% from its current market value. According to analyst projections, CTXR’s forecast low is $10.00 with $10.00 as the target high. To hit the forecast high, the stock’s price needs a -380.77% plunge from its current level, while the stock would need to soar -380.77% for it to hit the projected low.
Citius Pharmaceuticals Inc. (CTXR) estimates and forecasts
Data shows that the Citius Pharmaceuticals Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 8.90% over the past 6 months, a 35.56% in annual growth rate that is considerably higher than the industry average of 18.20%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Citius Pharmaceuticals Inc. will rise 45.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.00%. The 2021 estimates are for Citius Pharmaceuticals Inc. earnings to increase by 42.00%.
Citius Pharmaceuticals Inc. is expected to release its next quarterly earnings report between August 12 and August 16.
Citius Pharmaceuticals Inc. (NASDAQ:CTXR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.43% of Citius Pharmaceuticals Inc. shares while 22.17% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 24.21%. There are 22.17% institutions holding the Citius Pharmaceuticals Inc. stock share, with Blackrock Inc. the top institutional holder. As of Jun 29, 2021, the company held 43.87% of the shares, roughly 8.12 million CTXR shares worth $28.27 million.
Vanguard Group, Inc. (The) holds the second largest percentage of outstanding shares, with 30.52% or 5.65 million shares worth $19.67 million as of Jun 29, 2021.
Among Mutual Funds, the top two as of Jun 29, 2021 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 3.33 million shares estimated at $11.58 million under it, the former controlled 17.96% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 14.11% of the shares, roughly 2.61 million shares worth around $9.09 million.